Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2009 1
2011 2
2012 2
2013 4
2014 9
2015 7
2016 7
2017 20
2018 17
2019 25
2020 69
2021 1078
2022 858
Text availability
Article attribute
Article type
Publication date

Search Results

1,922 results
Results by year
Filters applied: . Clear all
Page 1
mRNA vaccine for cancer immunotherapy.
Miao L, Zhang Y, Huang L. Miao L, et al. Mol Cancer. 2021 Feb 25;20(1):41. doi: 10.1186/s12943-021-01335-5. Mol Cancer. 2021. PMID: 33632261 Free PMC article. Review.
However, mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. ...This review provides a detailed overview of the recent progress and existing challenges of mRNA cancer vaccines and future conside …
However, mRNA vaccine applications have been limited by instability, innate immunogenicity, and inefficient in vivo delivery. …
BNT162b2 mRNA COVID-19 Vaccine: First Approval.
Lamb YN. Lamb YN. Drugs. 2021 Mar;81(4):495-501. doi: 10.1007/s40265-021-01480-7. Drugs. 2021. PMID: 33683637 Free PMC article. Review.
BNT162b2 (Comirnaty(); BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. ...
BNT162b2 (Comirnaty(); BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the preve …
mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.
Xu S, Yang K, Li R, Zhang L. Xu S, et al. Int J Mol Sci. 2020 Sep 9;21(18):6582. doi: 10.3390/ijms21186582. Int J Mol Sci. 2020. PMID: 32916818 Free PMC article. Review.
It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis. At the same time, some suggestions for future mRNA vaccine development about storage methods, safety concerns, and personal …
It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosi …
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally VV, Romero JR, Talbot HK, Lee GM, Daley MF, Oliver SE. Gargano JW, et al. MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34237049 Free PMC article.
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine and the Moderna COVID-19 (mRNA-1273) vaccine,() and the Advisory Committee on Immunization Practices (ACIP) …
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for the Pfizer-BioNTech COVID-19 (BNT162 …
Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.
Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Linares-Fernández S, et al. Trends Mol Med. 2020 Mar;26(3):311-323. doi: 10.1016/j.molmed.2019.10.002. Epub 2019 Nov 5. Trends Mol Med. 2020. PMID: 31699497 Review.
mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humoral responses. ...This recognition can be either beneficial in activating antigen-presenting cells (APCs) or detrimental by indirectly blocki
mRNA vaccine platforms present numerous advantages, such as versatility, rapid production, and induction of cellular and humor
Addressing the Cold Reality of mRNA Vaccine Stability.
Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Crommelin DJA, et al. J Pharm Sci. 2021 Mar;110(3):997-1001. doi: 10.1016/j.xphs.2020.12.006. Epub 2020 Dec 13. J Pharm Sci. 2021. PMID: 33321139 Free PMC article.
In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain. We then review the literature on the pharmaceutical stability of mRNA
In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA v
mRNA vaccine: a potential therapeutic strategy.
Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X. Wang Y, et al. Mol Cancer. 2021 Feb 16;20(1):33. doi: 10.1186/s12943-021-01311-z. Mol Cancer. 2021. PMID: 33593376 Free PMC article. Review.
Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based delivery, peptide-based delivery, virus-like replicon particle and cationic nanoemulsion), naked mRNA vaccines and dendritic cells-based …
Therefore, to address the problem, scientists further exploited carrier-based mRNA vaccines (lipid-based delivery, polymer-based deli …
Herpes zoster emergence following mRNA COVID-19 vaccine.
Eid E, Abdullah L, Kurban M, Abbas O. Eid E, et al. J Med Virol. 2021 Sep;93(9):5231-5232. doi: 10.1002/jmv.27036. Epub 2021 May 3. J Med Virol. 2021. PMID: 33913545 Free PMC article. No abstract available.
HIV and Messenger RNA (mRNA) Vaccine.
Khalid K, Padda J, Khedr A, Ismail D, Zubair U, Al-Ewaidat OA, Padda S, Cooper AC, Jean-Charles G. Khalid K, et al. Cureus. 2021 Jul 5;13(7):e16197. doi: 10.7759/cureus.16197. eCollection 2021 Jul. Cureus. 2021. PMID: 34367800 Free PMC article. Review.
Even after 40 years, no cure has been developed for this pandemic. The development of the mRNA vaccine has led to further research for the utilization of mRNA vaccine in HIV, in attempts to create a prophylactic and therapeutic treatment. Although mess …
Even after 40 years, no cure has been developed for this pandemic. The development of the mRNA vaccine has led to further rese …
Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice.
Islam MA, Rice J, Reesor E, Zope H, Tao W, Lim M, Ding J, Chen Y, Aduluso D, Zetter BR, Farokhzad OC, Shi J. Islam MA, et al. Biomaterials. 2021 Jan;266:120431. doi: 10.1016/j.biomaterials.2020.120431. Epub 2020 Oct 1. Biomaterials. 2021. PMID: 33099060 Free PMC article.
Synthetic mRNA represents an exciting cancer vaccine technology for the implementation of effective cancer immunotherapy. ...Our findings indicate that C16-R848 adjuvant pulsation to mRNA vaccine NP is a rational design strategy to increase the effecti …
Synthetic mRNA represents an exciting cancer vaccine technology for the implementation of effective cancer immunotherapy. ...O …
1,922 results